Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK
Newbury Pharmaceuticals is delighted to announce the receipt of a sales order, scheduled for delivery in May 2024, from an customer located in a key international growth market. The value of this order is approximately 8.8 million SEK.
Mr. Lars Minor, CEO of Newbury, expressed his enthusiasm: "This order underscores the strength of our international sales efforts and contributes to our sales growth. It arrives at an opportune time, aligning with the introduction of our new products in Scandinavia. We are committed to leveraging such opportunities to enhance our presence both in our core markets and internationally."
The international sales activities are managed by Newbury's dedicated subsidiary in Switzerland. While Newbury maintains a strong focus on the Scandinavian market, it is actively exploring and capitalizing on international sales opportunities to bolster its overall sales and profitability.